[1]
|
Peters, S., Creelan, B., Hellmann, M.D., et al. (2017) Abstract CT082: Impact of Tumor Mutation Burden on the Efficacy of First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer: An Exploratory Analysis of CheckMate 026. Cancer Research, 77, CT082-CT082. https://doi.org/10.1158/1538-7445.AM2017-CT082
|
[2]
|
Gandara, D.R., Paul, S.M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., Rittmeyer, A., Fehrenbacher, L., Otto, G., Malboeuf, C., Lieber, D.S., Lipson, D., Silterra, J., Amler, L., Riehl, T., Cummings, C.A., Hegde, P.S., Sandler, A., Ballinger, M., Fabrizio, D., Mok, T. and Shames, D.S. (2018) Blood-Based Tumor Mutational Burden as a Predictor of Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Atezolizumab. Nature Medicine, 24, 1441-1448. https://doi.org/10.1038/s41591-018-0134-3
|
[3]
|
Hellmann, M.D., Ciuleanu, T.E., Pluzanski, A., Lee, J.S., Otterson, G.A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., Borghaei, H., Ramalingam, S.S., Brahmer, J., Reck, M., O’Byrne, K.J., Geese, W.J., Green, G., Chang, H., Szustakowski, J., Bhagavatheeswaran, P., Healey, D., Fu, Y., Nathan, F. and Paz-Ares, L. (2018) Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. The New England Journal of Medicine, 378, 2093-2104. https://doi.org/10.1056/NEJMoa1801946
|
[4]
|
Ricciuti, B., Kravets, S., Dahlberg, S.E., Umeton, R., Albayrak, A., Subegdjo, S.J., Johnson, B.E., Nishino, M., Sholl, L.M. and Awad, M.M. (2019) Use of Targeted Next Generation Sequencing to Characterize Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibition in Small Cell Lung Cancer. The Journal for ImmunoTherapy of Cancer, 7, Article No. 87. https://doi.org/10.1186/s40425-019-0572-6
|
[5]
|
Hellmann, M.D., Callahan, M.K., Awad, M.M., Calvo, E., Ascierto, P.A., Atmaca, A., Rizvi, N.A., Hirsch, F.R., Selvaggi, G., Szustakowski, J.D., Sasson, A., Golhar, R., Vitazka, P., Chang, H., Geese, W.J. and Antonia, S.J. (2018) Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell, 33, 853-861.E4. https://doi.org/10.1016/j.ccell.2018.04.001
|
[6]
|
Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., Wang, Q., Bai, H., Han, J., Tian, Y., Lu, J., Xu, T., Zhao, X., Wang, G., Cao, X., Li, F., Wang, D., Chen, Y., Bai, Y., Zhao, J., Zhao, Z., Zhang, Y., Xiong, L., He, J., Gao, S. and Wang, J. (2019) Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients with Non-Small Cell Lung Cancer with Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncology, 5, 696-702. https://doi.org/10.1001/jamaoncol.2018.7098
|
[7]
|
Chan, T.A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S.A., Stenzinger, A. and Peters, S. (2019) Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic. Annals of Oncology, 30, 44-56. https://doi.org/10.1093/annonc/mdy495
|
[8]
|
Langer, C.J., Gadgeel, S.M., Borghaei, H., Papadimitrakopoulou, V.A., Patnaik, A., Powell, S.F., Gentzler, R.D., Martins, R.G., Stevenson, J.P., Jalal, S.I., Panwalkar, A., Yang, J.C., Gubens, M., Sequist, L.V., Awad, M.M., Fiore, J., Ge, Y., Raftopoulos, H., Gandhi, L. and KEYNOTE-021 Investigators (2016) Carboplatin and Pemetrexed with or without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label KEYNOTE-021 Study. The Lancet Oncology, 17, 1497-1508. https://doi.org/10.1016/S1470-2045(16)30498-3
|
[9]
|
Horinouchi, H., Nogami, N., Saka, H., Nishio, M., Tokito, T., Takahashi, T., Kasahara, K., Hattori, Y., Ichihara, E., Adachi, N., Noguchi, K., Souza, F. and Kurata, T. (2021) Pembrolizumab plus Pemetrexed-Platinum for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: KEYNOTE-189 Japan Study. Cancer Science, 112, 3255-3265. https://doi.org/10.1111/cas.14980
|
[10]
|
Łuksza, M., Riaz, N., Makarov, V., Balachandran, V.P., Hellmann, M.D., Solovyov, A., Rizvi, N.A., Merghoub, T., Levine, A.J., Chan, T.A., Wolchok, J.D. and Greenbaum, B.D. (2017) A Neoantigen Fitness Model Predicts Tumour Response to Checkpoint Blockade Immunotherapy. Nature, 551, 517-520. https://doi.org/10.1038/nature24473
|
[11]
|
Melosky, B., Chu, Q., Juergens, R.A., Leighl, N., Ionescu, D., Tsao, M.S., McLeod, D. and Hirsh, V. (2018) Breaking the Biomarker Code: PD-L1 Expression and Checkpoint Inhibition in Advanced NSCLC. Cancer Treatment Reviews, 65, 65-77. https://doi.org/10.1016/j.ctrv.2018.02.005
|
[12]
|
Landre, T., Des Guetz, G., Chouahnia, K., Taleb, C., Vergnenègre, A. and Chouaïd, C. (2020) First-Line PD-1/PD-L1 Inhibitor plus Chemotherapy vs Chemotherapy Alone for Negative or < 1% PD-L1-Expressing Metastatic Non-Small-Cell Lung Cancers. Journal of Cancer Research and Clinical Oncology, 146, 441-448. https://doi.org/10.1007/s00432-019-03070-3
|
[13]
|
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M.J., Powell, S.F., Cheng, S.Y., Bischoff, H.G., Peled, N., Grossi, F., Jennens, R.R., Reck, M., Hui, R., Garon, E.B., Boyer, M., Rubio-Viqueira, B., Novello, S., Kurata, T., Gray, J.E., Vida, J., Wei, Z., Yang, J., Raftopoulos, H., Pietanza, M.C., Garassino, M.C. and KEYNOTE-189 Investigators (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 378, 2078-2092. https://doi.org/10.1056/NEJMoa1801005
|
[14]
|
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K.H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G.M., Piperdi, B., Kowalski, D.M. and KEYNOTE-407 Investigators (2018) Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 379, 2040-2051. https://doi.org/10.1056/NEJMoa1810865
|
[15]
|
Gadgeel, S.M., Pennell, N.A., Fidler, M.J., Halmos, B., Bonomi, P., Stevenson, J., Schneider, B., Sukari, A., Ventimiglia, J., Chen, W., Galasso, C., Wozniak, A., Boerner, J. and Kalemkerian, G.P. (2018) Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology, 13, 1393-1399. https://doi.org/10.1016/j.jtho.2018.05.002
|
[16]
|
Ready, N., Farago, A.F., De Braud, F., Atmaca, A., Hellmann, M.D., Schneider, J.G., Spigel, D.R., Moreno, V., Chau, I., Hann, C.L., Eder, J.P., Steele, N.L., Pieters, A., Fairchild, J. and Antonia, S.J. (2019) Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. Journal of Thoracic Oncology, 14, 237-244. https://doi.org/10.1016/j.jtho.2018.10.003
|
[17]
|
Ready, N.E., Ott, P.A., Hellmann, M.D., Zugazagoitia, J., Hann, C.L., De Braud, F., Antonia, S.J., Ascierto, P.A., Moreno, V., Atmaca, A., Salvagni, S., Taylor, M., Amin, A., Camidge, D.R., Horn, L., Calvo, E., Li, A., Lin, W.H., Callahan, M.K. and Spigel, D.R. (2020) Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results from the CheckMate 032 Randomized Cohort. Journal of Thoracic Oncology, 15, 426-435. https://doi.org/10.1016/j.jtho.2019.10.004
|
[18]
|
Gaule, P., Smithy, J.W., Toki, M., Rehman, J., Patell-Socha, F., Cougot, D., Collin, P., Morrill, P., Neumeister, V. and Rimm, D.L. (2017) A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncology, 3, 256-259. https://doi.org/10.1001/jamaoncol.2016.3015
|
[19]
|
Hong, L., Negrao, M.V., Dibaj, S.S., Chen, R., Reuben, A., Bohac, J.M., Liu, X., Skoulidis, F., Gay, C.M., Cascone, T., Mitchell, K.G., Tran, H.T., Le, X., Byers, L.A., Sepesi, B., Altan, M., Elamin, Y.Y., Fossella, F.V., Kurie, J.M., Lu, C., Mott, F.E., Tsao, A.S., Rinsurongkawong, W., Lewis, J., Gibbons, D.L., Glisson, B.S., Blumenschein, G.R., Roarty, E.B., Futreal, P.A., Wistuba, I.I., Roth, J.A., Swisher, S.G., Papadimitrakopoulou, V.A., Heymach, J.V., Lee, J.J., Simon, G.R. and Zhang, J. (2020) Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit from Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 15, 1449-1459. https://doi.org/10.1016/j.jtho.2020.04.026
|
[20]
|
Herbst, R.S., Baas, P., Perez-Gracia, J.L., Felip, E., Kim, D.W., Han, J.Y., Molina, J.R., Kim, J.H., Dubos Arvis, C., Ahn, M.J., Majem, M., Fidler, M.J., Surmont, V., De Castro, G., Garrido, M., Shentu, Y., Emancipator, K., Samkari, A., Jensen, E.H., Lubiniecki, G.M. and Garon, E.B. (2019) Use of Archival versus Newly Collected Tumor Samples for Assessing PD-L1 Expression and Overall Survival: An Updated Analysis of KEYNOTE-010 Trial. Annals of Oncology, 30, 281-289. https://doi.org/10.1093/annonc/mdy545
|
[21]
|
Tsao, M.S., Kerr, K.M., Kockx, M., Beasley, M.B., Borczuk, A.C., Botling, J., Bubendorf, L., Chirieac, L., Chen, G., Chou, T.Y., Chung, J.H., Dacic, S., Lantuejoul, S., Mino-Kenudson, M., Moreira, A.L., Nicholson, A.G., Noguchi, M., Pelosi, G., Poleri, C., Russell, P.A., Sauter, J., Thunnissen, E., Wistuba, I., Yu, H., Wynes, M.W., Pintilie, M., Yatabe, Y. and Hirsch, F.R. (2018) PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology, 13, 1302-1311. https://doi.org/10.1016/j.jtho.2018.05.013
|
[22]
|
Uryvaev, A., Passhak, M., Hershkovits, D., Sabo, E. and Bar-Sela, G. (2018) The Role of Tumor-Infiltrating Lymphocytes (TILs) as a Predictive Biomarker of Response to Anti-PD1 Therapy in Patients with Metastatic Non-Small Cell Lung Cancer or Metastatic Melanoma. Medical Oncology, 35, Article No. 25. https://doi.org/10.1007/s12032-018-1080-0
|
[23]
|
Niemeijer, A.N., Sahba, S., Smit, E.F., Lissenberg-Witte, B.I., De Langen, A.J. and Thunnissen, E. (2020) Association of Tumour and Stroma PD-1, PD-L1, CD3, CD4 and CD8 Expression with DCB and OS to Nivolumab Treatment in NSCLC Patients Pre-Treated with Chemotherapy. British Journal of Cancer, 123, 392-402. https://doi.org/10.1038/s41416-020-0888-5
|
[24]
|
Nakazawa, N., Yokobori, T., Kaira, K., Turtoi, A., Baatar, S., Gombodorj, N., Handa, T., Tsukagoshi, M., Ubukata, Y., Kimura, A., Kogure, N., Ogata, K., Maeno, T., Sohda, M., Yajima, T., Shimizu, K., Mogi, A., Kuwano, H., Saeki, H. and Shirabe, K. (2020) High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells Were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors. Annals of Surgical Oncology, 27, 933-942. https://doi.org/10.1245/s10434-019-07878-8
|
[25]
|
Thommen, D.S., Koelzer, V.H., Herzig, P., Roller, A., Trefny, M., Dimeloe, S., Kiialainen, A., Hanhart, J., Schill, C., Hess, C., Savic, Prince, S., Wiese, M., Lardinois, D., Ho, P.C., Klein, C., Karanikas, V., Mertz, K.D., Schumacher, T.N. and Zippelius, A. (2018) A Transcriptionally and Functionally Distinct PD-1 CD8 T Cell Pool with Predictive Potential in Non-Small-Cell Lung Cancer Treated with PD-1 Blockade. Nature Medicine, 24, 994-1004. https://doi.org/10.1038/s41591-018-0057-z
|
[26]
|
Cai, M.C., Zhao, X., Cao, M., Ma, P., Chen, M., Wu, J., Jia, C., He, C., Fu, Y., Tan, L., Xue, X., Yu, Z. and Zhuang, G. (2020) T-Cell Exhaustion Interrelates with Immune Cytolytic Activity to Shape the Inflamed Tumor Microenvironment. The Journal of Pathology, 251, 147-159. https://doi.org/10.1002/path.5435
|
[27]
|
Kim, H., Kwon, H.J., Han, Y.B., Park, S.Y., Kim, E.S., Kim, S.H., Kim, Y.J., Lee, J.S. and Chung, J.H. (2019) Increased CD3 T Cells with a Low FOXP3 /CD8 T Cell Ratio Can Predict Anti-PD-1 Therapeutic Response in Non-Small Cell Lung Cancer Patients. Modern Pathology, 32, 367-375. https://doi.org/10.1038/s41379-018-0142-3
|
[28]
|
Sato, M., Watanabe, S., Tanaka, H., Nozaki, K., Arita, M., Takahashi, M., Shoji, S., Ichikawa, K., Kondo, R., Aoki, N., Hayashi, M., Ohshima, Y., Koya, T., Ohashi, R., Ajioka, Y. and Kikuchi, T. (2019) Retrospective Analysis of Antitumor Effects and Biomarkers for Nivolumab in NSCLC Patients with EGFR Mutations. PLOS ONE, 14, e0215292. https://doi.org/10.1371/journal.pone.0215292
|
[29]
|
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J.I., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Morishita, Y., Kashiwabara, K., Takazawa, M., Ohara, O., Kakimi, K. and Nakajima, J. (2017) An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. Journal of Thoracic Oncology, 12, 791-803. https://doi.org/10.1016/j.jtho.2017.01.005
|
[30]
|
Hardy-Werbin, M., Rocha, P., Arpi, O., et al. (2019) Serum Cytokine Levels as Predictive Biomarkers of Benefit from Ipilimumab in Small Cell Lung Cancer. Oncoimmunology, 8, e1593810. https://doi.org/10.1080/2162402X.2019.1593810
|
[31]
|
李兴, 马丽娜, 李迅, 等. PD-1抑制剂治疗晚期肺癌的疗效及对患者外周血T淋巴细胞亚群和细胞因子水平的影响[J]. 中国肿瘤生物治疗杂志, 2021, 28(11): 1113-1118.
|
[32]
|
Wu, L., Xie, S., Wang, L., et al. (2021) The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients with Lung Cancer to Anti-PD-1 Immunotherapy Combined with Chemotherapy. Frontiers in Immunology, 12, Article ID: 665147. https://doi.org/10.3389/fimmu.2021.665147
|
[33]
|
Boutsikou, E., Domvri, K., Hardavella, G., et al. (2018) Tumour Necrosis Factor, Interferon-Gamma and Interleukins as Predictive Markers of Antiprogrammed Cell-Death Protein-1 Treatment in Advanced Non-Small Cell Lung Cancer: A Pragmatic Approach in Clinical Practice. Therapeutic Advances in Medical Oncology, 10, 1758835918768238. https://doi.org/10.1177/1758835918768238
|
[34]
|
郑轩, 胡毅. 晚期非小细胞肺癌患者抗PD-1治疗前后血清TNF-α水平变化与疗效的关系[J]. 解放军医学院学报, 2019, 40(3): 231-234 55.
|
[35]
|
左秀萍, 高苗, 宋娟, 等. 非小细胞肺癌患者中Th17细胞及IL-17变化与淋巴结转移、不良预后的相关性分析[J]. 临床肺科杂志, 2021, 26(9): 1405-1410.
|
[36]
|
毛英, 刘黎, 张匠, 等. 非小细胞肺癌患者癌组织免疫微环境中Th1、Th2、Th17的表达水平及意义[J]. 临床误诊误治, 2021, 34(1): 77-82.
|
[37]
|
陈样, 勾红峰. 白介素-7与肿瘤关系的研究进展[J]. 实用医院临床杂志, 2016, 13(4): 212-214.
|
[38]
|
黄作平, 邹冰心, 谢强, 等. Th_1/Th_2类细胞因子在非小细胞肺癌中的作用探讨[J]. 中国现代医学杂志, 2006(13): 1948-1951.
|
[39]
|
Wei, X., Gu, L. and Heng, W. (2021) T Lymphocytes Related Biomarkers for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer. Oncology Letters, 21, Article No. 89. https://doi.org/10.3892/ol.2020.12350
|
[40]
|
Manjarrez-Orduño, N., Menard, L.C., Kansal, S., et al. (2018) Circulating T Cell Subpopulations Correlate with Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer. Frontiers in Immunology, 9, Article No. 1613. https://doi.org/10.3389/fimmu.2018.01613
|
[41]
|
Dusselier, M., Deluche, E., Delacourt, N., Ballouhey, J., Egenod, T., Melloni, B., Vergnenègre, C., Veillon, R. and Vergnenègre, A. (2019) Neutrophil-to-Lymphocyte Ratio Evolution Is an Independent Predictor of Early Progression of Second-Line Nivolumab-Treated Patients with Advanced Non-Small-Cell Lung Cancers. PLOS ONE, 14, e0219060. https://doi.org/10.1371/journal.pone.0219060
|
[42]
|
Routy, B., Le Chatelier, E., Derosa, L., Duong, C.P.M., Alou, M.T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M.P., Fidelle, M., Flament, C., Poirier-Colame, V., Opolon, P., Klein, C., Iribarren, K., Mondragón, L., Jacquelot, N., Qu, B., Ferrere, G., Clémenson, C., Mezquita, L., Masip, J.R., Naltet, C., Brosseau, S., Kaderbhai, C., Richard, C., Rizvi, H., Levenez, F., Galleron, N., Quinquis, B., Pons, N., Ryffel, B., Minard-Colin, V., Gonin, P., Soria, J.C., Deutsch, E., Loriot, Y., Ghiringhelli, F., Zalcman, G., Goldwasser, F., Escudier, B., Hellmann, M.D., Eggermont, A., Raoult, D., Albiges, L., Kroemer, G. and Zitvogel, L. (2018) Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors. Science, 359, 91-97. https://doi.org/10.1126/science.aan3706
|
[43]
|
Goldberg, S.B., Narayan, A., Kole, A.J., Decker, R.H., Teysir, J., Carriero, N.J., Lee, A., Nemati, R., Nath, S.K., Mane, S.M., Deng, Y., Sukumar, N., Zelterman, D., Boffa, D.J., Politi, K., Gettinger, S.N., Wilson, L.D., Herbst, R.S. and Patel, A.A. (2018) Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clinical Cancer Research, 24, 1872-1880. https://doi.org/10.1158/1078-0432.CCR-17-1341
|
[44]
|
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M.A., Du, V.Y., Schlessinger, J., Goldberg, S.B., Chiang, A., Sanmamed, M.F., Melero, I., Agorreta, J., Montuenga, L.M., Lifton, R., Ferrone, S., Kavathas, P., Rimm, D.L., Kaech, S.M., Schalper, K., Herbst, R.S. and Politi, K. (2017) Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery, 7, 1420-1435. https://doi.org/10.1158/2159-8290.CD-17-0593
|
[45]
|
Wu, Q., Liu, J., Zhang, Y., Wu, S. and Xie, X. (2020) Predictive Value of Positron Emission Tomography for the Prognosis of Immune Checkpoint Inhibitors (ICIs) in Malignant Tumors. Cancer Immunology, Immunotherapy, 69, 927-936. https://doi.org/10.1007/s00262-020-02515-w
|
[46]
|
Kobayashi, M., Ikezoe, T., Uemura, Y., Ueno, H. and Taguchi, H. (2007) Long-Term Survival of a Patient with Small Cell Lung Cancer Associated with Cancer-Associated Retinopathy. Lung Cancer, 57, 399-403. https://doi.org/10.1016/j.lungcan.2007.02.015
|